GLP-1 and Thyroid: The Boxed Warning

The short answer

Every long-acting GLP-1 medication — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda — carries a black box warning about thyroid C-cell tumors. The warning is based on rodent studies in which the drug class produced medullary thyroid carcinoma (MTC) at clinically relevant exposures. Whether this translates to humans is unknown after roughly two decades of class use. The drugs are absolutely contraindicated in anyone with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN-2).

What the research says

The boxed warning comes from rat carcinogenicity studies. In two-year studies, semaglutide and other long-acting GLP-1 receptor agonists caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors — both adenomas and carcinomas — at clinically relevant exposures. The same finding appeared with liraglutide before semaglutide and with tirzepatide after. The mechanism appears to involve sustained activation of GLP-1 receptors on thyroid C cells, which produce calcitonin.

Species matter here. Rats have far more GLP-1 receptors on thyroid C cells than humans do. C-cell hyperplasia is also a much more common background finding in rats than in humans. That biology is the reason the FDA could not extrapolate "rat MTC" directly to "human MTC risk" — the label notes that human relevance "cannot be determined."

Post-marketing surveillance is the closest thing to human data on this question. The class has been on market in some form since 2005 (exenatide, short-acting) and 2010 (liraglutide, long-acting), with hundreds of millions of patient-doses now logged. No clear signal of increased MTC incidence has emerged at population level. Several large observational studies and meta-analyses have looked specifically at thyroid cancer outcomes; results have been mixed, with some suggesting a small signal for thyroid cancer overall but not specifically for MTC. None have been strong enough to revise the label beyond the existing boxed warning.

Calcitonin monitoring is sometimes raised as a question. The FDA label does not recommend routine baseline or follow-up serum calcitonin or thyroid ultrasound, in part because the predictive value of those tests for early MTC in low-risk individuals is poor and likely to generate more harm (unnecessary biopsies) than benefit. The recommendation is symptom-based monitoring: a neck lump, persistent hoarseness, trouble swallowing, or shortness of breath while on therapy warrants prompt evaluation.

What this means for you

If you have a personal or family history of MTC or MEN-2, you cannot take a GLP-1. This is the hardest stop on the label. The contraindication includes any first-degree relative with MTC, including diagnoses you may not have known about. It is worth checking with family before starting therapy if MTC has ever been mentioned in your family history.

If you have a known benign thyroid nodule, papillary thyroid cancer history (which is biologically different from MTC), or Hashimoto's, the GLP-1 thyroid warning does not directly apply. Your provider may still want to know about your thyroid history for completeness, but those conditions are not the contraindication the boxed warning is targeting.

If you develop symptoms on therapy — a new neck lump, persistent hoarseness for more than a couple of weeks, trouble swallowing, or unexplained shortness of breath — that warrants prompt evaluation, regardless of how long you have been on the drug. The base rate of MTC in the general population is very low, but the warning exists for a reason, and symptom-driven workup is the recommended approach.

Common questions

Keep exploring

Browse all GLP-1 guides.